08:00 Wed 17 Jun 2020
Evgen Pharma PLC - SFX-01 to be evaluated in COVID-19 trial
("Evgen" or the "Company")
SFX-01 to be evaluated in COVID-19 trial
SFX-01 upregulates the Nrf2 pathway which is part of the natural human defence against inflammatory and oxidative stress, such as the inflammation that occurs during a severe viral infection. Preclinical studies have shown that up-regulating the Nrf2 pathway reduces the severity of ARDS, the progressive lung damage observed in COVID-19 patients which can result in the need for invasive ventilation in an intensive care unit.
The trial is being led by Professor
Evgen will supply clinical centres with SFX-01 and a placebo as its contribution to the trial. No additional financing is required as the costs of providing SFX-01 for the trial are not material.
The clinical study is being supported by a grant from
Professor
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
Enquiries:
Evgen Pharma plc www.evgen.com |
via Walbrook |
|
|
|
|
|
|
|
|
|
|
finnCap www.finncap.com |
+44 (0)20 7220 0500 |
|
|
|
|
|
|
|
|
|
|
Walbrook PR |
+44 (0)20 7933 87870 or evgen@walbrookpr.com |
|
|
+44 (0)7980 541 893 / +44 (0)7876 741 001 |
|
About Evgen
Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.
The Company commenced operations in
For further information, please visit: www.evgen.com
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE